FDA Clearance Tracker · P040018
ADVIA CENTAUR HAV IGM READY PACK REAGENTS, ADVIA CENTAUR HAV IGM QUALITY CONTROL MATERIALS
Last checked: Nov 20, 2026Latest source record: Dec 22, 2004 (this decision)Source: openFDAMethods & limitations
Decided
Dec 22, 2004
Approved (reclassified)
Time to decision
265 days
Received Apr 1, 2004. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class II
The decision
- FDA number
- P040018
- Device name
- ADVIA CENTAUR HAV IGM READY PACK REAGENTS, ADVIA CENTAUR HAV IGM QUALITY CONTROL MATERIALS
- Applicant
- Bayer Healthcare, LLC
- Applicant location
- Tarrytown, NY
- Received
- Apr 1, 2004
- Decided
- Dec 22, 2004
- Decision
- Approved (reclassified)
Device type
- Device class
- Class II
- Regulation
- 21 CFR 866.3310
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
APPROVAL FOR THE ADVIA CENTAUR HAV IGM. HAV IGM READYPACK REAGENTS: THIS DEVICE IS INDICATED FOR USE FOR THE ADVIA CENTAUR HAV IGM ASSAY AND IS AN IN VITRO DIAGNOSTIC IMMUNOASSAY FOR THE QUALITATIVE DETERMINATION OF IGM RESPONSE TO THE HEPATITIS A VIRUS (HAV) IN HUMAN SERUM OR PLASMA (POTASSIUM EDTA, LITHIUM OR SODIUM HEPARINIZED) USING THE ADVIA CENTAUR SYSTEM. THE ASSAY IS INTENDED FOR USE AS AN AID IN THE DIAGNOSIS OF ACUTE OR RECENT INFECTION (USUALLY 6 MONTHS OR LESS) WITH HEPATITIS A VIRUS. HAV IGM QUALITY CONTROL MATERIALS: THE CONTROLS ARE INDICATED FOR IN VITRO DIAGNOSTIC USE IN MONITORING THE PERFORMANCE OF THE HAV IGM ASSAY ON THE ADVIA CENTAUR SYSTEMS. THE PERFORMANCE OF THE HAV IGM QUALITY CONTROL MATERIAL HAS NOT BEEN ESTABLISHED WITH ANY OTHER ANTI-HAV IGM ASSAYS.
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code LOL. The earliest in FDA's data is P780012, decided Jan 19, 1979.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for Bayer Healthcare, LLC
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K171802 · Decided Mar 7, 2018 · 261 days after receipt
Device type: Stimulator, Nerve, Transcutaneous, Over-The-Counter (NUH) · Neurology & Neurosurgery
1 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.